Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EC$17.29-0.11(-0.63%)Ecopetrol announces the dates for the presentation of its third quarter 2026 results report and conference call Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) (the "Company") announces that on Tuesday, November 10, 2026, it plans to release its financial and...[9:58:00 PM ET]KMB$108.00-1.63(-1.49%)Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the extension of the expiration date of the offers to exchange (each an...[9:29:00 PM ET]AOS$62.06+0.15(+0.24%)A. O. Smith Announces Majority Interest of China Business Acquired by CPE; A. O. Smith to Retain 19% Stake and Long-Term Brand License Global water technology company A. O. Smith Corporation ("A. O. Smith" or "the Company") (NYSE: AOS) today announced definitive agreements with CPE,...[8:55:00 PM ET]TOPS$0.31+0.03(+10.36%)TOP Ships Inc. Announces $5.0 Million Private Placement of Senior Convertible Notes and Warrants[8:54:57 PM ET]PAC$224.01-0.66(-0.29%)Grupo Aeroportuario del Pacífico Announces Dividend Payment Date as Approved at the Annual General Ordinary Shareholders’ Meeting[8:53:07 PM ET]TOPS$0.31+0.03(+10.36%)TOP Ships Inc. Announces Reverse Stock Split[8:43:02 PM ET]BTCWF$0.08-0.00(-5.00%)Bluesky Digital Announces Director Change[8:02:00 PM ET]CCL$27.72+0.86(+3.20%)Princess Cruises Sets the Stage for Extraordinary Discovery Down Under in 2028-29 Princess Cruises unveils its 2028–29 Australia and New Zealand season alongside the 2029 Grand World Odyssey. Together, this collection offers four...[8:00:00 PM ET]HTHIY$36.02+0.56(+1.58%)Hitachi Unveils a New Global Digital Services Company Turning Cloud, Data and AI Into Measurable Business Outcomes: Hitachi Digital[8:00:00 PM ET]BFH$102.61+0.89(+0.87%)Bread Financial Announces Pricing of an Offering of Depositary Shares Representing Interests in Its Series C Preferred Stock[7:52:45 PM ET]

LBRX · NASDAQ

LB Pharmaceuticals Inc

$39.67 +0.64 (+1.64%)

Company overview

Clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases, including schizophrenia and bipolar depression. Lead candidate is LB-102, a methylated derivative of amisulpride.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.3B
Employees
16
Headquarters
New York, NY
Website
lbpharma.us
CEO
Heather D. Turner
Listed
September 11, 2025
P/E
-1.85
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$82,000
Operating income
-$46.9M
EBITDA
-$46.2M
Net income
-$39.2M
EPS
-$21.47
Total assets
$393M
Total debt
$3.5M
Earnings yield
-54.12%

Price chart

25.4231.8438.2744.6951.11
LBRX 1D NASDAQ O39.14H40.15L38.77C39.68+0.33 (+0.85%)Vol54.67K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
LBRXLB Pharmaceuticals Inc Stock news LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia MarketBeat
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals to Participate in Upcoming Investor Events GlobeNewswire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress GlobeNewswire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment GlobeNewsWire
LBRXLB Pharmaceuticals Inc Stock news This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Benzinga
LBRXLB Pharmaceuticals Inc Stock news LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity Seeking Alpha
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. GlobeNewsWire
LBRXLB Pharmaceuticals Inc Stock news IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target? Investors Business Daily
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals to Participate in Upcoming September Investor Events GlobeNewswire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer GlobeNewsWire
LBRXLB Pharmaceuticals Inc Stock news Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday Benzinga
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia GlobeNewsWire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals to Participate in Upcoming June Investor Events GlobeNewsWire
LBRXLB Pharmaceuticals Inc Stock news All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy Zacks Investment Research
LBRXLB Pharmaceuticals Inc Stock news LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe News Wire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia GlobeNewsWire
LBRXLB Pharmaceuticals Inc Stock news LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript Seeking Alpha
LBRXLB Pharmaceuticals Inc Press release LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference GlobeNewsWire
See more
FAQ

Questions about LB Pharmaceuticals Inc

What does LB Pharmaceuticals Inc do?
Clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases, including schizophrenia and bipolar depression. Lead candidate is LB-102, a methylated derivative of amisulpride.
What is LBRX's market cap?
LB Pharmaceuticals Inc (LBRX) is a listed stock with a live quote. The latest market cap on this page is $1.3B.
Where is LB Pharmaceuticals Inc headquartered?
LB Pharmaceuticals Inc is headquartered in New York, NY.
How do I get LBRX news from the API?
Call GET /v1/news?tickers=LBRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does LBRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for LBRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the LBRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs